palisadebio
Manufacturing · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4600 S Syracuse St Ste 900, Denver, Colo...Phone Number
(858) 704-4900Website
www.palisadebio.comRevenue
-Stock Symbol
PALIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About palisadebio
Palisade Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing innovative therapies intended to address serious autoimmune, inflammatory, and fibrotic diseases that have significant unmet medical needs. The company concentrates on advancing precision medicine by applying scientific research to develop therapeutic candidates designed to improve treatment outcomes while reducing unwanted systemic effects commonly associated with conventional therapies. Through its research-driven business model, Palisade Bio seeks to create novel drug candidates capable of delivering targeted therapeutic benefits for patients suffering from chronic and difficult-to-treat diseases.Explore more
palisadebio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is palisadebio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once palisadebio has new funding data
Congratulate Masked Content for being promoted to Masked Content at palisadebio
Earning: See what the market has to say on palisadebio recently announced quarterly report
Check out if palisadebio is spiking on competitors!
Product Launch: Get notified when palisadebio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if palisadebio had a recent Job posting/layoffs
palisadebio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if palisadebio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at palisadebio
Find 3 more new buyers
Compare Similar Companies to palisadebio
Compare insights from companies similar to palisadebio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
palisadebio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
palisadebio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about palisadebio.
palisadebio financials insights
Gather financial insights about palisadebio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$3.9M
2026
Private Equity
$500K
palisadebio Tech Stack
A closer look at the technologies used by palisadebio
See more technologies
Most Recent Scoops
Project
Palisade Bio is expecting IND clearance for its lead ulcerative colitis program in H1 2026, with a first patient dose anticipated in H2 2026 and an efficacy readout planned for H2 2027, while its Crohn's disease program is targeting IND clearance in H2 of this year, first subject dosing by year-end, and interim and primary readouts in H1 2028.
Clinical Operations
Earnings
Earnings, Finance
Project
Palisade Bio has reported that its PALI-2108 is an oral, novel, locally-targeted drug with a dual mechanism of action (anti-inflammatory and anti-fibrotic) designed to improve tolerability compared to existing oral therapies in the IBD space.
Product Development, Pharmaceuticals
Project
Palisade Bio has reported that its Phase 1B study of PALI-2108 in ulcerative colitis showed a 63% improvement in modified Mayo score, 100% response rate, and 40% clinical remission rate after just one week of treatment, including a five-day titration period.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
palisadebio News & Media
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertisePalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachPalisade Bio to Participate in the Jefferies Global Healthcare Conference
Management presentation to take place on Thursday, June 4th at 3:45 PM ETPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding palisadebio
Sign Up For FreeTo access detailed company insights
Palisade Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing innovative therapies intended to address serious autoimmune, inflammatory, and fibrotic diseases that have significant unmet medical needs. The company concentrates on advancing precision medicine by applying scientific research to develop therapeutic... Read More
